Lung cancer deaths are predicted to increase dramatically, according to a recent report from the World Health Organization (WHO). Lung cancer is expected to become more prominent in the underdeveloped world as a result of an anticipated rise in the use of tobacco products, which is the primary cause of approximately 80 percent of all lung cancer. The WHO “Report On The Global Tobacco Epidemic” projects that lung cancer incidence will increase from 18 million cases in the 20th century to 180 million cases in the 21st century worldwide. The majority of lung cancer cases are expected to be concentrated in 10 countries: China (30 percent of all cases), India (10 percent), Indonesia, Russia, the United States, Japan, Brazil, Bangladesh, Germany and Turkey... Accuray 's Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
March
(46)
- Masimo Rainbow SET Pulse CO-Oximetry Effective as ...
- Lilly : US$4.4 Million to the WHO for MDR-TB Progr...
- Nereus Pharmaceuticals : Clinical Trail of NPI-235...
- Masimo : Schiller AG Adopts its Rainbow SET as The...
- Accuray : CyberKnife Radiosurgery Used to Treat Lu...
- Actavis : approval of generic Wellbutrin SR and Zy...
- Merck Statement on the FDA Early Communication of ...
- Kamada : Advancement in its Phase II Trial with Ae...
- EpiCept, Myriad Genetics, Azixa
- Poniard Pharmaceuticals : Additional data presenta...
- AstraZeneca : Phase III Studies Of The Investigati...
- SPO Medical : Shipping PulseOx 6000(TM) and PulseO...
- MicroDose Technologies : Global License to Merck &...
- Mpex Pharmaceuticals : MP-376, Granted U.S. Orphan...
- Arriva Pharmaceuticals : Phase 2b Development of L...
- Cell Therapeutics : European Marketing Authorizati...
- Allegro Diagnostics : to Develop and Commercialize...
- AstraZeneca : Long-Term SYMBICORT® Use In Children...
- Apieron : FDA Clearance of the Insight™ eNO System...
- Genaera : MedImmune Initiation of Phase 2A Trial o...
- MAP Pharmaceuticals : Positive Results From Compar...
- GlobeImmune, Initiation of a Phase 2a Clinical Tri...
- Tongjitang to Enhance Product Portfolio with a Lea...
- AlphaMed Pharmaceuticals has successfully expresse...
- Universal Detection Technology , Anti-Microbial Pr...
- ArQule, Phase 1/2 Clinical Trial Program of ARQ 19...
- Novelos Therapeutics, Pivotal Phase 3 Lung Cancer ...
- Abbott, Genentech, Roche and OSI, Collaboration on...
- Luminex and Abbott, Agreement for Global Distribut...
- Quidel's QuickVue RSV Test : FDA Grants CLIA Waiver
- Altor BioScience , Tissue Factor Antagonists from ...
- Introgen's p53 Immunotherapy INGN 225 in Patients ...
- Inspire, Second Phase 3 Cystic Fibrosis Trial
- Expression Pathology, Research in Identifying Biom...
- Biothera’s Imprime PGG with Avastin Against Cancer
- Response Genetics, ResponseDX Tests to Select Inst...
- Gilead, Aztreonam Lysine 75 mg Powder for Nebulise...
- Alnylam, First Human Proof of Concept for an RNAi ...
- Aerocrine, NIOX MINO: a New Hand-Held Device to Me...
- KaloBios, Phase 1/2 Trial of KB002 Engineered Mono...
- Cerner and UNMHSC, agreement to evaluate dry-powde...
- Talecris Biotherapeutics, 20th Anniversary of Laun...
- Amira Pharmaceuticals and GSK, global agreement fo...
- Asthmatx, Bronchial Thermoplasty in Refractory Ast...
- Orexo, eoxins, new mechanism for asthma and COPD t...
- Boehringer Ingelheim’s BIBW 2992 for the treatment...
-
▼
March
(46)
Mar 28, 2008
Accuray : CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
March 26, 2008– Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced that approximately 90 percent of CyberKnife centers worldwide are now treating lung cancer with the CyberKnife® Robotic Radiosurgery System*. The number of lung cancer patients is growing significantly as well, with more than 5,000 individuals receiving CyberKnife treatments to date.